Patient | Age/sex | SpA Type | HLA-B27 | Disease Duration, yrs | Previous DMARD | Previous Biologic | Associated DMARD | Steroids, mg/day | Extraarticular Features | Associated Diseases |
---|---|---|---|---|---|---|---|---|---|---|
1 | 46 M | PsA periph | 20 | AZA, LEF, MTX, gold | ETA, IFX, ADA | 0 | 10 | 0 | 0 | |
2 | 37 F | AS | + | 8 | SSZ | ETA, IFX, ADA | 0 | 0 | 0 | 0 |
3 | 49 M | SpA periph | 16 | MTX, SSZ, LEF, gold | ETA, IFX | 0 | 10 | 0 | 0 | |
4 | 31 F | SpA axial, periph | 8 | MTX, SSZ, AZA | ETA, IFX ADA | MTX | 0 | Crohn PSO | 0 | |
5 | 61 F | PsA axial, periph | 13 | MTX, SSZ, gold | ETA, ADA | MTX | 20 | PSO | 0 | |
6 | 38 M | AS + oligo | − | 15 | MTX, SSZ, CTX | ETA, IFX | 0 | 7 | Uveitis | 0 |
7 | 64 F | PsA periph | 10 | MTX, SSZ LEF, gold | IFX | MTX | 40 | PSO | 0 | |
8 | 62 M | AS axial | + | 40 | MTX, SSZ | 0 | 0 | 0 | 0 | MGUS bladder cancer, HTA |
9 | 56 F | PsA periph, axial | 25 | MTX, SSZ LEF, gold | ETA, IFX, ADA | MTX | 0 | PSO | 0 | |
10 | 34 F | AS axial | + | 12 | MTX, HCQ | ETA, IFX | MTX | 50 | Uveitis | 0 |
11 | 65 M | AS axial, periph | + | 3 | SSZ | ETA, ADA | 0 | 0 | PSO Uveitis | Diabetes, coronaropathy |
12 | 69 F | PsA periph | 6 | MTX, LEF HCQ, CYC | 0 | 0 | 0 | PSO | MGUS, TB history | |
13 | 69 M | SpA PSO | NA | MTX, SSZ, LEF | ETA, IFX ADA | LEF | 0 | PSO | MGUS, prostate cancer, coronaropathy | |
14 | 35 F | PsA periph | NA | MTX, LEF | ETA, IFX ADA | 0 | 5 | PSO | 0 | |
15 | 56 M | PsA periph | 6 | MTX, SSZ | ETA, IFX ADA | 0 | 15 | PSO | 0 | |
16 | 60 M | AS axial, periph | + | 7 | MTX | ETA, IFX ADA | SSZ | 0 | 0 | HTA |
17 | 20 F | PsA periph | 2 | MTX, LEF, HCQ | ETA | 0 | 0 | |||
18 | 65 F | SpA periph | + | 4 | MTX | ETA, ADA | LEF | 0 | Uveitis, Crohn | Diabetes |
19 | 56 M | AS axial | + | 16 | MTX | ETA, IFX ADA | MTX | 0 | 0 | 0 |
20 | 36 M | AS axial, periph | 18 | MTX, SSZ | ETA, IFX ADA | 0 | 0 | 0 | Still’s disease history | |
21 | 39 M | SpA | + | 18 | SSZ | ETA | 0 | 0 | 0 | Chondrosarcoma history |
22 | 61 F | PsA periph, axial | 13 | MTX, SSZ, gold | ETA, ADA | MTX | 15 | PSO | ||
23 | 55 M | PsA periph, axial | 7 | MTX, SSZ | ADA, ABA | MTX | 0 | PSO | MS | |
24 | 76 M | SpA axial, periph | 9 | MTX, AZA | IFX | MTX | 5 | Crohn | Diabetes, digestive cancer | |
25 | 55 F | AS axial | + | 21 | 0 | 0 | 0 | 0 | PSO | 0 |
26 | 41 F | AS axial, periph | + | 16 | SSZ | ETA, IFX, ADA | 0 | 0 | 0 | Vasculitis |
PsA: psoriatic arthritis; periph: predominantly peripheral involvement; AS: ankylosing spondylitis; SpA: spondyloarthritis; AZA: azathioprine; MTX: methotrexate; LEF: leflunomide; SSZ: sulfasalazine; HCQ: hydroxychloroquine; CTX: cyclophosphamide; CYC: cyclosporine; gold: gold salts (allochry-sine); ETA: etanercept; ADA: adalimumab; IFX: infliximab; ABA: abatacept; PSO: psoriasis; MGUS: monoclonal gammopathy of undetermined significance; HTA: arterial hypertension; TB: tuberculosis; Crohn: Crohn’s disease; MS: multiple sclerosis.